The Use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to Assess the Effects of Anti-neoplastic Therapy on Tumor Associated Vasculature
- Evaluate the ability of positron emission tomography (PET) to assess the effect of
therapy directed against tumor vasculatures on tumor blood flow and tumor blood volume
in patients enrolled on a treatment protocol evaluating a therapeutic modality
effecting the tumor associated vasculature.
- Evaluate the ability of PET to assess the effects of this type of therapy regimen on
tumor uptake of fluorodeoxyglucose in these patients.
- Evaluate the ability of magnetic resonance imaging (MRI) to assess the effects of
therapy directed against the tumor vasculature on tumor blood flow and tumor vascular
density in these patients.
- Compare the findings on PET and/or MRI with those obtained from conventional CT in this
OUTLINE: This is a diagnostic study conducted concurrently with a therapeutic modality
Patients have magnetic resonance imaging and/or positron emission tomography (PET) scans
performed prior to start of therapy, 6 weeks and 16 weeks following the initiation of
therapy, and 6 weeks following the completion of therapy. Each scan requires about 1-3
hours. Patients receive up to 3 different PET scans including tumor blood flow scan with
H2015, tumor blood volume scan with 11CO, and glucose uptake scan with fludeoxyglucose F 18.
PROJECTED ACCRUAL: A total of 145 patients will be accrued for this study within 2 years.
Primary Purpose: Diagnostic
Steven K. Libutti, MD
NCI - Surgery Branch
United States: Food and Drug Administration
|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office||Bethesda, Maryland 20892-1182|